Current affairs commentator Victor Gao shares his view on Glaxosmithkline (GSK)'s scandal.

Q1. Probes sparked by GSK's unfolding corruption scandal are underway, and it is still too early to identify the source of the problem. Is it the lack of clear guidelines and protocols for the UK drugmaker, or the wrongdoing of some of its money-chasing employees in China? Where do you think the problems lie?

Q2. The bribery scandal also exposed problems in China's healthcare industry. Can you explain for us the problems or loopholes, and what measures should be taken to iron out the kinks in the industry?

(CNTV.cn July 24, 2013)